I noticed some in this recent cohort had 177lu and 255ac. I can see how this would've played a part in how well patients would've responded to cu67. If 255ac isn't approved, why would the FDA consider having 255ac as a prereq for P3?
Despite all this, 44% had PSA over 50% on a single dose(pluvicto was ~46%).
- Forums
- ASX - By Stock
- CU6
- Ann: Theranostic prostate cancer trial advances to multi-dose
Ann: Theranostic prostate cancer trial advances to multi-dose, page-21
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
Add CU6 (ASX) to my watchlist
(20min delay)
|
|||||
Last
$5.57 |
Change
0.480(9.43%) |
Mkt cap ! $1.735B |
Open | High | Low | Value | Volume |
$5.20 | $5.57 | $5.16 | $14.63M | 2.711M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6146 | $5.57 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.60 | 6194 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 535 | 5.750 |
1 | 106 | 5.710 |
1 | 280 | 5.650 |
1 | 1500 | 5.630 |
4 | 251 | 5.610 |
Price($) | Vol. | No. |
---|---|---|
5.450 | 77 | 1 |
5.520 | 1300 | 1 |
5.600 | 2160 | 3 |
5.750 | 2974 | 2 |
5.770 | 2000 | 1 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |